Oramed Pharmaceuticals Launches Phase 1A Trials Of Its Insulin Suppository
Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB), a developer of alternative drug delivery systems, announced today that it has received approval from the South Africa Medicines Control Council (MCC) to begin conducting Phase 1A trials on eight healthy human volunteers for ORMD 0802, the company’s newly developed insulin suppository.
More: continued here
Filed under: Clinical Trials on October 27th, 2008